Clinical Trials Browser

INDUSTRY × pembrolizumab × 1 year × Clear all

NCT03486873 2026-06-05

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04634877 2026-06-05

KEYNOTE-B21

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05017012 2026-06-05

MK-3475A-C18

Phase 1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT06385080 2026-06-05

OrigAMI-4

Phase 1/2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06901531 2026-06-05

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT07063745 2026-06-05

MountainTAP-29

Phase 2/3 Recruiting

Lung Neoplasms

NCT07276399 2026-06-05

OrigAMI-5

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07302347 2026-06-05

MK-3475-G21

Phase 1/2 Recruiting

DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT07353957 2026-06-05

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms

NCT07475806 2026-06-05

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

Muscle-invasive Bladder Cancer

NCT05920356 2026-06-04

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06480552 2026-06-04

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06772623 2026-06-04

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07222566 2026-06-04

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT07578649 2026-06-04

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

Phase 3 Not yet recruiting

Endometrial Neoplasms

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT04619797 2026-06-03

SKYSCRAPER-06

Phase 2/3 Completed

542 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT05062980 2026-06-03

Acclaim-2

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05579366 2026-06-03

RAINFOL-01

Phase 1/2 Recruiting

BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05797168 2026-06-03

FONTANA

Phase 1/2 Recruiting

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT06119581 2026-06-03

SUNRAY-01

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06890598 2026-06-03

SUNRAY-02

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06952504 2026-06-03

TroFuse-033

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07218380 2026-06-03

FORAGER-2

Phase 3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07247110 2026-06-03

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Phase 1 Recruiting

Neoplasms

NCT07361510 2026-06-03

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07431827 2026-06-03

KANDLELIT-013

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase 1 Recruiting

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07622186 2026-06-03

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04083599 2026-06-02

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05787587 2026-06-02

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related, Breast Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06057038 2026-06-02

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Malignant Solid Tumor

NCT06151574 2026-06-02

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Active not recruiting

Lung Neoplasms

NCT06525220 2026-06-02

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT06635824 2026-06-02

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Phase 3 Active not recruiting

Lung Neoplasms

NCT06788990 2026-06-02

FORTIFI-HN01

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT06875310 2026-06-02

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06917079 2026-06-02

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT06984328 2026-06-02

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

Melanoma, Recurrence

NCT07046923 2026-06-02

A Study of LY4175408 in Participants With Advanced Cancer

Phase 1 Recruiting

BreastGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02332668 2026-06-01

MK-3475-051

Phase 1/2 Recruiting

DermatologicLymphoid

Lymphoma, Melanoma

NCT04736173 2026-06-01

ARC-10

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04938817 2026-06-01

KEYNOTE-B98

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT06422143 2026-06-01

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06558799 2026-06-01

LUNAR-4

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06600321 2026-06-01

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Phase 1 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT06788912 2026-06-01

MK-3475-01E

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06966700 2026-06-01

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07195695 2026-06-01

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07216703 2026-06-01

TroFuse-036

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms